Myriad Genetics Inc

MYGN XNAS IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

Market Cap

410M

Short interest (May 15)

8.8%

Net Short (Jun 03 ): -0.2%

Borrow Fee

0.66%

↓ 8.0%

Available Shares

5M

↓ 4.8%

Price Chart

Company Overview

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Company Info

Exchange: NASDAQ
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
CIK: 0000899923
Asset Type: CS

Market Data

Market Cap: $407,071,785
Employees: 2,700
Status: Active

Short Interest

Current Borrow Fee 0.66%
Range: 0.40% - 0.66%
Available Shares 5M
Range: 1.6M - 5.4M

Recent Changes

Fee Change: ↓ 30.0%
Available Change: ↑ 5.8%

Quick Actions

View Dilution Chart
Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime